CN114945570A - 雌激素受体调节剂的盐和形式 - Google Patents

雌激素受体调节剂的盐和形式 Download PDF

Info

Publication number
CN114945570A
CN114945570A CN202080093201.4A CN202080093201A CN114945570A CN 114945570 A CN114945570 A CN 114945570A CN 202080093201 A CN202080093201 A CN 202080093201A CN 114945570 A CN114945570 A CN 114945570A
Authority
CN
China
Prior art keywords
degrees
compound
pharmaceutically acceptable
acceptable salt
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093201.4A
Other languages
English (en)
Chinese (zh)
Inventor
黄琴华
萨伊·盖亚南·海格
凯文·杜安·邦克
约翰·奈特
黛博·海伦·斯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricoram Ip Holding Co ltd
Original Assignee
Ricoram Ip Holding Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricoram Ip Holding Co ltd filed Critical Ricoram Ip Holding Co ltd
Publication of CN114945570A publication Critical patent/CN114945570A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080093201.4A 2019-11-04 2020-11-02 雌激素受体调节剂的盐和形式 Pending CN114945570A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930153P 2019-11-04 2019-11-04
US62/930,153 2019-11-04
PCT/US2020/058526 WO2021091819A1 (en) 2019-11-04 2020-11-02 Salts and forms of an estrogen receptor modulator

Publications (1)

Publication Number Publication Date
CN114945570A true CN114945570A (zh) 2022-08-26

Family

ID=75849360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093201.4A Pending CN114945570A (zh) 2019-11-04 2020-11-02 雌激素受体调节剂的盐和形式

Country Status (12)

Country Link
US (1) US20220389006A1 (https=)
EP (1) EP4045507A4 (https=)
JP (1) JP2022553833A (https=)
KR (1) KR20220103977A (https=)
CN (1) CN114945570A (https=)
AU (1) AU2020380211A1 (https=)
BR (1) BR112022008520A2 (https=)
CA (1) CA3159749A1 (https=)
IL (1) IL292680A (https=)
MX (1) MX2022005139A (https=)
TW (1) TW202132294A (https=)
WO (1) WO2021091819A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638869A (zh) * 2018-09-07 2021-04-09 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201028414A (en) * 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
WO2021216671A1 (en) * 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638869A (zh) * 2018-09-07 2021-04-09 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
CN112638869B (zh) * 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法

Also Published As

Publication number Publication date
TW202132294A (zh) 2021-09-01
EP4045507A4 (en) 2023-11-01
MX2022005139A (es) 2022-06-24
AU2020380211A1 (en) 2022-05-19
CA3159749A1 (en) 2021-05-14
US20220389006A1 (en) 2022-12-08
IL292680A (en) 2022-07-01
BR112022008520A2 (pt) 2022-07-26
JP2022553833A (ja) 2022-12-26
WO2021091819A1 (en) 2021-05-14
EP4045507A1 (en) 2022-08-24
KR20220103977A (ko) 2022-07-25

Similar Documents

Publication Publication Date Title
JP2023533040A (ja) Ｗｅｅ１阻害剤の塩及び形態
ES2909390T3 (es) Formas sólidas cristalinas de sales de N-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, procedimientos de fabricación y procedimientos de uso
AU2021383928A1 (en) Fgfr inhibitors and methods of making and using the same
CN112321579A (zh) 2-氨基-1-羟乙基-8-羟基喹啉-2(1h)-酮衍生物的盐
JP2021527031A (ja) セピアプテリンの薬学的に許容される塩
TW201215605A (en) Manufacturing process for pyrimidine derivatives
RU2624446C9 (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
TW201028142A (en) Heterobicyclic sphingosine 1-phosphate analogs
CN114945570A (zh) 雌激素受体调节剂的盐和形式
KR20130112848A (ko) 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
JP2015199763A (ja) トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
JP2022507558A (ja) チエノピリドン誘導体のカリウム塩一水和物及びその調製方法
US12552737B2 (en) Salts of (2R, 6R)-hydroxynorketamine, their crystal forms, and methods of making the same
TWI267511B (en) Process for preparing 10,11-methanobenzosuberane derivatives
CN106459025A (zh) 6‑[(4r)‑4‑甲基‑1，1‑二氧化‑1，2，6‑噻二嗪烷‑2‑基]异喹啉‑1‑腈的结晶形式
CN105566302A (zh) 二氢吲哚酮化合物及其盐的结晶
JP2024508497A (ja) 医薬組成物、その製造方法及び使用
CN105732642A (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN116082302A (zh) 氘代吲唑-吡啶-苯基-三氟乙基四取代烯烃类化合物及其用途
HK40109762A (zh) (z)-因多昔芬的组合物和其富集方法
HK40087700A (zh) 墨蝶呤的药学上可接受的盐
HK40026069A (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
HK40026069B (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination